by Natasha Davie | Dec 10, 2013
. The UK has previously committed to incorporating some sort of value based pricing into its reimbursement scheme to improve patient access to innovative medicines. With recent backtracking on this decision, as the Jan 2014 deadline for this integration approaches, we...
by Nick Dragojlovic | Dec 2, 2013
> As the expiration of the California Institute for Regenerative Medicine’s (CIRM) funding approaches, the fate of CIRM after 2017 is top of mind for stem cell researchers in the state. While the agency’s leadership appears to be leaning towards some form of...
by Alessandra Pasut | Nov 28, 2013
> There’s no better pleasure in life than to satisfy our own cravings. Whether it’s a food craving or something else, there’s no peace for the soul, at least mine, till that need is quenched. And for those of us who find themselves longing for (more) stem cells,...
by Mark Curtis | Nov 27, 2013
. Welcome to the regenerative medicine deal review for the month of November. Cytori Therapeutics and Lorem Vascular have teamed up to catalyze the commercialization of Cytori cell therapies using its proprietary Celution® System in Asia. There was also a notable deal...
by Stacey Johnson | Nov 15, 2013
. Sometimes too much choice can be a bad thing. It paralyzes you. I was flummoxed by the many options available to me in selecting what to feature on Right Turn this week. Then it struck me: I have the perfect item right under my nose (so to speak). CCRM just launched...
by Alessandra Pasut | Oct 15, 2013
> As scientists we’d like to think and even take a bit of pride knowing our research is as value-free as it could be, detached from any political, economical or societal forces and influences. Yet history teaches us how basic research discoveries, from...
Comments